Director Maier details ProQR (PRQR) share option grants and vesting

Rhea-AI Filing Summary

ProQR Therapeutics N.V. director Martin Alexander Maier reported his holdings of share options that give him the right to buy Ordinary Shares at fixed prices. The filing lists several option grants with exercise prices between $1.02 and $3.41 per share and expirations from 2032 through 2035.

The derivative positions include options over 500 Ordinary Shares at an exercise price of $1.02 expiring on February 29, 2032, and additional options over 500 shares at $3.41 and 500 shares at $1.98. Larger grants cover 14,186 shares at $1.90, 22,128 shares at $2.65, and 25,192 shares at $2.02, with staggered expiration dates. Footnotes explain that some options are fully vested, while others vest 25% on specified dates such as January 1, 2024, January 1, 2025, May 22, 2025, January 1, 2026, and January 1, 2027, with the remaining 75% vesting in 12 substantially equal quarterly installments, subject to his continuous service.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Maier Martin Alexander

(Last) (First) (Middle)

PROQR THERAPEUTICS N.V.

ZERNIKEDREEF 9

(Street)

LEIDEN 2333 CK

(City) (State) (Zip)

NETHERLANDS

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
ProQR Therapeutics N.V. [ PRQR ]

3a. Foreign Trading Symbol
[N/A]

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	(1)	02/29/2032	Ordinary Shares	500	$1.02	D
Share Option (Right to Buy)	(2)	12/31/2032	Ordinary Shares	500	$3.41	D
Share Option (Right to Buy)	(3)	12/31/2033	Ordinary Shares	500	$1.98	D
Share Option (Right to Buy)	(4)	05/22/2033	Ordinary Shares	14,186	$1.9	D
Share Option (Right to Buy)	(5)	12/31/2034	Ordinary Shares	22,128	$2.65	D
Share Option (Right to Buy)	(6)	12/31/2035	Ordinary Shares	25,192	$2.02	D

Explanation of Responses:

1. Fully vested.

2. 25% of the shares subject to such option vest and become exercisable on January 1, 2024, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

3. 25% of the shares subject to such option vest and become exercisable on January 1, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

4. 25% of the shares subject to such option vest and become exercisable on May 22, 2025, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

5. 25% of the shares subject to such option vest and become exercisable on January 1, 2026, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

6. 25% of the shares subject to such option vest and become exercisable on January 1, 2027, and the remaining 75% vest in 12 substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Pieter Erik de Ridders, Attorney-in-Fact	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the ProQR (PRQR) Form 3 filing by Martin Alexander Maier report?

The Form 3 filing reports director Martin Alexander Maier’s existing share option holdings in ProQR Therapeutics N.V. It lists several option grants over Ordinary Shares, detailing exercise prices, expiration dates, and vesting schedules, but does not show any new purchases or sales.

What share option positions does Martin Alexander Maier hold in ProQR (PRQR)?

Maier holds multiple share options to buy ProQR Ordinary Shares, including 500-share grants at exercise prices of $1.02, $3.41, and $1.98. He also has larger grants over 14,186 shares at $1.90, 22,128 shares at $2.65, and 25,192 shares at $2.02.

When do Martin Alexander Maier’s ProQR (PRQR) share options expire?

The options expire on various dates between 2032 and 2035. Specific expirations include February 29, 2032, December 31, 2032, May 22, 2033, December 31, 2033, December 31, 2034, and December 31, 2035, as listed for each grant.

How do the vesting schedules work for Maier’s ProQR (PRQR) options?

Footnotes describe options where 25% of the shares vest and become exercisable on dates such as January 1, 2024, January 1, 2025, May 22, 2025, January 1, 2026, and January 1, 2027. The remaining 75% vest in 12 substantially equal quarterly installments, subject to continuous service.

Does the ProQR (PRQR) Form 3 show any insider buying or selling by Martin Alexander Maier?

The data classify all entries as holdings, with no buy or sell transactions reported. Transaction codes and summary fields show no purchases, sales, exercises, gifts, or tax-withholding events, indicating this filing simply records existing derivative positions rather than new trading activity.

What type of securities are covered in Martin Alexander Maier’s ProQR (PRQR) Form 3?

All reported positions are “Share Option (Right to Buy)” derivatives over ProQR Ordinary Shares. Each line item specifies the option’s exercise price, expiration date, and the number of underlying Ordinary Shares it covers, providing a detailed snapshot of his option-based exposure.